


## CONTINUING MEDICAL EDUCATION ΣΥΝΕΧΙΖΟΜΕΝΗ ΙΑΤΡΙΚΗ ΕΚΠΑΙΔΕΥΣΗ

### Clinical Immunology Quiz – Case 5

Peripheral blood from a 10-year old female was referred to the Immunology Lab for immunophenotyping. The patient complained for recurrent upper respiratory tract infections and otitis media during the last year while a history of frequent infections was recorded since infancy. Although, the absolute number of lymphocyte subsets was into normal ranges (fig. 1 and tab. 1), the patient displayed a mild hypogammaglobulinemia (tab. 1). Although the patient did not fulfill the diagnostic criteria for the diagnosis of common variable immunodeficiency (CVID),



**Figure 1.** Flow cytometry analysis showing normal lymphocyte subsets.

**Table 1.** Lymphocyte subsets and serum immunoglobulins of the patient.

Blood lymphocyte subpopulations ( $\times 10^9/L$ )		
Total lymphocyte count	4.217	(2.9–5.1)
T lymphocytes		
CD3	3.163	(1.8–3.2)
CD4	1.718	(1.0–1.8)
CD8	1.242	(0.3–0.6)
B lymphocytes		
CD19	0.577	(0.3–0.6)
Quantitative serum immunoglobulins (mg/dL)		
IgG	919	(934–1640)
IgA	51	(85–242)
IgM	47	(100–252)

ARCHIVES OF HELLENIC MEDICINE 2008, 25(4):548–549  
 ΑΡΧΕΙΑ ΕΛΛΗΝΙΚΗΣ ΙΑΤΡΙΚΗΣ 2008, 25(4):548–549

G. Loules,  
 F. Kalala,  
 A. Mamara,  
 E. Tsitsami,  
 M. Speletas


Department of Immunology and  
 Histocompatibility, Medical School,  
 University of Thessaly, Larissa, Greece

a molecular analysis of *TNFRSF13B* gene (encoding TACI) was performed.

Interestingly, the patient was double heterozygous in *TNFRSF13B*, carrying the mutations V220A and P251L (fig. 2). Further analysis demonstrated that her parents were *TNFRSF13B* heterozygotes but did not display hypogammaglobulinemia.

#### Comment

*TACI* (Transmembrane Activator, calcium modulator and Cyclophilin ligand Interactor) is a transmembrane receptor, which mediates isotype switching in B cells. Recently, 6 mutations (in homozygous or heterozygous state) in *TNFRSF13B* gene were found to be present in 10% to 20% of patients with CVID, implying the contribution of this gene in the disease pathogenesis and/or phenotype. However, *TNFRSF13B* mutations were reported in normal



**Figure 2.** Molecular analysis of *TNFRSF13B* gene, showing the presence of the V220A and P251L mutations.

*individuals, indicating possibly that when alone do not necessarily predispose to CVID pathogenesis. Nevertheless, their presence could be considered as an early indicator of CVID emergence, considering that in several CVID patients the diagnosis is underestimated and a delayed diagnosis can lead to increased morbidity and mortality. Thus, in our patient, persistent hypogammaglobulinemia and recurrent infections are followed-up for Ig replacement to be considered.*

*Corresponding author:*

M. Speletas, Department of Immunology and Histocompatibility, Medical School, University of Thessaly, University Hospital of Larissa, GR-411 10 Larissa, Greece, Tel: +302410681862, Fax: +302410682580, e-mail: [maspel@med.uth.gr](mailto:maspel@med.uth.gr)